WO2002080969A1 - Remedes pour des maladies liees a l'arthrite chronique du nourrisson - Google Patents

Remedes pour des maladies liees a l'arthrite chronique du nourrisson Download PDF

Info

Publication number
WO2002080969A1
WO2002080969A1 PCT/JP2002/003312 JP0203312W WO02080969A1 WO 2002080969 A1 WO2002080969 A1 WO 2002080969A1 JP 0203312 W JP0203312 W JP 0203312W WO 02080969 A1 WO02080969 A1 WO 02080969A1
Authority
WO
WIPO (PCT)
Prior art keywords
remedies
chronic arthritis
infant
infant chronic
relating diseases
Prior art date
Application number
PCT/JP2002/003312
Other languages
English (en)
French (fr)
Inventor
Kazuyuki Yoshizaki
Norihiro Nishimoto
Masahiro Iwamoto
Seiji Minota
Shumpei Yokota
Takako Miyamae
Original Assignee
Chugai Seiyaku Kabushiki Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26612973&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2002080969(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to UA2003109818A priority Critical patent/UA80091C2/uk
Priority to KR1020037012661A priority patent/KR100842133B1/ko
Priority to JP2002579008A priority patent/JP3702274B2/ja
Application filed by Chugai Seiyaku Kabushiki Kaisha filed Critical Chugai Seiyaku Kabushiki Kaisha
Priority to BR0208636-0A priority patent/BR0208636A/pt
Priority to HU0303952A priority patent/HU230197B1/hu
Priority to NZ528479A priority patent/NZ528479A/en
Priority to PL365339A priority patent/PL216534B1/pl
Priority to US10/473,165 priority patent/US20040115197A1/en
Priority to MXPA03008955A priority patent/MXPA03008955A/es
Priority to EP02708772A priority patent/EP1374900A4/en
Priority to EP19196253.9A priority patent/EP3640261A1/en
Priority to AU2002243032A priority patent/AU2002243032B2/en
Priority to CA2443294A priority patent/CA2443294C/en
Priority to IL15807902A priority patent/IL158079A0/xx
Publication of WO2002080969A1 publication Critical patent/WO2002080969A1/ja
Priority to IL158079A priority patent/IL158079A/en
Priority to NO20034388A priority patent/NO20034388L/no
Priority to HK04105346.6A priority patent/HK1062408A1/xx
Priority to US11/704,233 priority patent/US7955598B2/en
Priority to IL187604A priority patent/IL187604A/en
Priority to US13/064,953 priority patent/US9255145B2/en
Priority to US14/986,884 priority patent/US20160194401A1/en
Priority to US15/946,866 priority patent/US20180222988A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PCT/JP2002/003312 2001-04-02 2002-04-02 Remedes pour des maladies liees a l'arthrite chronique du nourrisson WO2002080969A1 (fr)

Priority Applications (22)

Application Number Priority Date Filing Date Title
UA2003109818A UA80091C2 (en) 2001-04-02 2002-02-04 Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
JP2002579008A JP3702274B2 (ja) 2001-04-02 2002-04-02 小児慢性関節炎関連疾患治療剤
AU2002243032A AU2002243032B2 (en) 2001-04-02 2002-04-02 Remdies for infant chronic arthritis-relating diseases
EP19196253.9A EP3640261A1 (en) 2001-04-02 2002-04-02 Therapeutic agent for chronic arthritides diseases of childhood-related diseases
BR0208636-0A BR0208636A (pt) 2001-04-02 2002-04-02 Agente terapêutico para doenças de artrìtides crÈnicas de doenças relacionadas com inf‰ncia
HU0303952A HU230197B1 (hu) 2001-04-02 2002-04-02 Terápiás ágens gyermekkori krónikus artrítiszhez hasonló betegségekre
NZ528479A NZ528479A (en) 2001-04-02 2002-04-02 Remedies for infant chronic arthritis-relating diseases
PL365339A PL216534B1 (pl) 2001-04-02 2002-04-02 Środek terapeutyczny do leczenia młodzieńczego reumatoidalnego zapalenia stawów o początku układowym i środek terapeutyczny do leczenia choroby Stilla wieku dorosłego
US10/473,165 US20040115197A1 (en) 2001-04-02 2002-04-02 Remedies for infant chronic arthritis-relating diseases
MXPA03008955A MXPA03008955A (es) 2001-04-02 2002-04-02 Agente terapeutico para enfermedades de tipo artritides cronicas o enfermedades relacionadas con la ninez.
CA2443294A CA2443294C (en) 2001-04-02 2002-04-02 Remedies for infant chronic arthritis-relating diseases
KR1020037012661A KR100842133B1 (ko) 2001-04-02 2002-04-02 소아 만성 관절염 관련질환 치료제
IL15807902A IL158079A0 (en) 2001-04-02 2002-04-02 Pharmaceutical compositions containing an interleukin-6 antagonist
EP02708772A EP1374900A4 (en) 2001-04-02 2002-04-02 MEDICINE FOR TREATING DISEASES RELATED TO CHRONIC ARTHRITIS IN INFANT CHILDREN
IL158079A IL158079A (en) 2001-04-02 2003-09-24 Pharmaceutical preparations containing interleukin-6 antagonist
NO20034388A NO20034388L (no) 2001-04-02 2003-10-01 Terapeutisk middel for kronisk artritt sykdommer i barne- relaterte sykdommer
HK04105346.6A HK1062408A1 (en) 2001-04-02 2004-07-21 Remedies for infant chronic arthritis-relating diseases
US11/704,233 US7955598B2 (en) 2001-04-02 2007-02-09 Therapeutic agent for chronic arthritides diseases of childhood-related diseases
IL187604A IL187604A (en) 2001-04-02 2007-11-25 Pharmaceuticals containing interlockin antagonist - 6 for the treatment of sitel disease
US13/064,953 US9255145B2 (en) 2001-04-02 2011-04-28 Therapeutic agent for chronic arthritides diseases of childhood-related diseases
US14/986,884 US20160194401A1 (en) 2001-04-02 2016-01-04 Therapeutic agent for chronic arthritides diseases of childhood-related diseases
US15/946,866 US20180222988A1 (en) 2001-04-02 2018-04-06 Therapeutic agent for chronic arthritides diseases of childhood-related diseases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001103627 2001-04-02
JP2001-103627 2001-04-02
JP2001-109131 2001-04-06
JP2001109131 2001-04-06

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10473165 A-371-Of-International 2002-04-02
US10/473,165 A-371-Of-International US20040115197A1 (en) 2001-04-02 2002-04-02 Remedies for infant chronic arthritis-relating diseases
US11/704,233 Division US7955598B2 (en) 2001-04-02 2007-02-09 Therapeutic agent for chronic arthritides diseases of childhood-related diseases

Publications (1)

Publication Number Publication Date
WO2002080969A1 true WO2002080969A1 (fr) 2002-10-17

Family

ID=26612973

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/003312 WO2002080969A1 (fr) 2001-04-02 2002-04-02 Remedes pour des maladies liees a l'arthrite chronique du nourrisson

Country Status (18)

Country Link
US (5) US20040115197A1 (ja)
EP (4) EP2298812A3 (ja)
JP (5) JP3702274B2 (ja)
KR (2) KR100842132B1 (ja)
CN (1) CN100562339C (ja)
AU (1) AU2002243032B2 (ja)
BR (1) BR0208636A (ja)
CA (1) CA2443294C (ja)
HK (1) HK1062408A1 (ja)
HU (1) HU230197B1 (ja)
IL (3) IL158079A0 (ja)
MX (1) MXPA03008955A (ja)
NO (1) NO20034388L (ja)
NZ (1) NZ528479A (ja)
PL (1) PL216534B1 (ja)
RU (2) RU2541165C2 (ja)
UA (1) UA80091C2 (ja)
WO (1) WO2002080969A1 (ja)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007525524A (ja) * 2004-02-26 2007-09-06 ベイラー・リサーチ・インスチチユート 関節炎の全身処置のための組成物および方法
WO2008078715A1 (ja) * 2006-12-27 2008-07-03 Chugai Seiyaku Kabushiki Kaisha Ｉｌ－６アンタゴニストを有効成分とする炎症性筋疾患治療剤
US7919095B2 (en) 2006-08-03 2011-04-05 Vaccinex, Inc. Anti-IL-6 monoclonal antibodies
EP2368577A2 (en) 2003-04-28 2011-09-28 Chugai Seiyaku Kabushiki Kaisha Methods for treating interleukin-6 related diseases
WO2011149046A1 (ja) 2010-05-28 2011-12-01 独立行政法人国立がん研究センター 膵癌治療剤
WO2011149051A1 (ja) 2010-05-28 2011-12-01 中外製薬株式会社 抗腫瘍t細胞応答増強剤
WO2013176471A1 (ko) 2012-05-21 2013-11-28 한국생명공학연구원 곰보배추의 추출물 또는 이의 분획물을 유효성분으로 포함하는, stat3 매개 질환의 예방 또는 치료용 약학적 조성물
CN103739669A (zh) * 2013-12-31 2014-04-23 罗瑞雪 一种抑制白介素-6多肽及其应用
US8945558B2 (en) 2005-10-21 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Methods for treating myocardial infarction comprising administering an IL-6 inhibitor
US9260516B2 (en) 2006-04-07 2016-02-16 Osaka University Method for promoting muscle regeneration by administering an antibody to the IL-6 receptor
US9725514B2 (en) 2007-01-23 2017-08-08 Shinshu University Chronic rejection inhibitor
US10662245B2 (en) 2008-09-26 2020-05-26 Chugai Seiyaku Kabushiki Kaisha Methods of reducing IL-6 activity for disease treatment
US10697883B2 (en) 2015-05-19 2020-06-30 National Center Of Neurology And Psychiatry Method for determining application of therapy to multiple sclerosis (MS) patient
US10717781B2 (en) 2008-06-05 2020-07-21 National Cancer Center Neuroinvasion inhibitor
US10774148B2 (en) 2015-02-27 2020-09-15 Chugai Seiyaku Kabushiki Kaisha Composition for treating IL-6-related diseases
US10782290B2 (en) 2013-06-11 2020-09-22 National Center Of Neurology And Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US11174317B2 (en) 2015-06-04 2021-11-16 National Center Of Neurology And Psychiatry Therapeutic agent for mental illness comprising IL-6 inhibitor as active ingredient
US11248053B2 (en) 2007-09-26 2022-02-15 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US11332533B2 (en) 2007-09-26 2022-05-17 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
US11359194B2 (en) 2008-04-11 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US11891434B2 (en) 2010-11-30 2024-02-06 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8017121B2 (en) * 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
EP0791359A4 (en) * 1994-10-21 2002-09-11 Chugai Pharmaceutical Co Ltd MEDICINE AGAINST IL-6 PRODUCTION IN DISEASES
AU736282B2 (en) 1997-03-21 2001-07-26 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell- mediated diseases comprising IL-6 antagonist as an active ingredient
US20020187150A1 (en) * 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
DE69937994T2 (de) * 1998-03-17 2008-12-24 Chugai Seiyaku K.K. Prophylaktische oder therapeutische mittel gegen entzündliche erkrankungen des verdauungstraktes enthaltend antagonistische il-6 rezeptor antikörper
JP4889187B2 (ja) * 2000-10-27 2012-03-07 中外製薬株式会社 Ｉｌ−６アンタゴニストを有効成分として含有する血中ｍｍｐ−３濃度低下剤
UA80091C2 (en) * 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
PL213311B1 (pl) * 2002-02-14 2013-02-28 Chugai Pharmaceutical Co Ltd Preparat roztworu zawierajacego przeciwcialo
JP4651541B2 (ja) * 2003-10-17 2011-03-16 中外製薬株式会社 中皮腫治療剤
US8617550B2 (en) * 2003-12-19 2013-12-31 Chugai Seiyaku Kabushiki Kaisha Treatment of vasculitis with IL-6 antagonist
AR048335A1 (es) 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
EP3269738A1 (en) 2004-03-24 2018-01-17 Chugai Seiyaku Kabushiki Kaisha Subtypes of humanized antibody against interleukin-6 receptor
CA2603408C (en) 2005-03-31 2018-08-21 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
WO2007074880A1 (ja) * 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
EP3345616A1 (en) 2006-03-31 2018-07-11 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
DK2041177T3 (da) 2006-06-02 2012-02-27 Regeneron Pharma Højaffinitetsantistoffer mod human IL-6-receptor
US8080248B2 (en) * 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
NZ601583A (en) * 2007-05-21 2013-08-30 Bristol Myers Squibb Co Novel rabbit antibody humanization methods and humanized rabbit antibodies
US20090238825A1 (en) * 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
BRPI0811782A2 (pt) * 2007-05-21 2019-02-26 Alder Biopharmaceuticals, Inc. anticorpos para il-6 e uso dos mesmos
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
BRPI0821110B8 (pt) 2007-12-05 2021-05-25 Chugai Pharmaceutical Co Ltd anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
WO2009140348A2 (en) 2008-05-13 2009-11-19 Novimmune Sa Anti-il-6/il-6r antibodies and methods of use thereof
US9452227B2 (en) * 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
TWI544077B (zh) 2009-03-19 2016-08-01 Chugai Pharmaceutical Co Ltd Antibody constant region change body
MA33405B1 (fr) 2009-05-15 2012-07-03 Chugai Pharmaceutical Co Ltd Anticorps anti-axl
EP2481752B1 (en) 2009-09-24 2016-11-09 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
BR112012009828B8 (pt) * 2009-10-26 2022-10-25 Hoffmann La Roche Método para a produção de uma imunoglobulina glicosilada e seu uso
JP5934652B2 (ja) 2009-11-24 2016-06-15 アルダーバイオ ホールディングス エルエルシー Ｉｌ−６に対する抗体およびその使用
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
US10435458B2 (en) 2010-03-04 2019-10-08 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variants with reduced Fcgammar binding
CA2817216A1 (en) 2010-11-08 2012-05-18 F. Hoffmann-La Roche Ag Subcutaneously administered anti-il-6 receptor antibody
ES2847891T3 (es) 2010-11-23 2021-08-04 Vitaeris Inc Anticuerpos anti-IL-6 para el tratamiento de la mucositis oral
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
JP6563910B2 (ja) 2013-07-04 2019-08-21 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 血清サンプル中の抗薬物抗体を検出するための干渉抑制イムノアッセイ
BR112016006197B1 (pt) 2013-09-27 2023-04-11 Chugai Seiyaku Kabushiki Kaisha Método para produzir um anticorpo biespecífico de polipeptídeos
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
CA2995645A1 (en) 2015-08-18 2017-02-23 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
AU2016381992B2 (en) 2015-12-28 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
WO2017147169A1 (en) 2016-02-22 2017-08-31 Ohio State Innovation Foundation Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin a analogues or metabolites, and estradiol metabolites
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
US11033496B2 (en) 2017-03-17 2021-06-15 The Regents Of The University Of Michigan Nanoparticles for delivery of chemopreventive agents
KR20200132938A (ko) 2018-03-15 2020-11-25 추가이 세이야쿠 가부시키가이샤 지카 바이러스에 대해 교차-반응성을 갖는 항-뎅기 바이러스 항체 및 사용 방법
BR112021014377A2 (pt) 2019-01-31 2021-12-28 Regeneron Pharma Composições e métodos para o tratamento de artrite idiopática juvenil
JP2022527972A (ja) 2019-04-02 2022-06-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 前悪性病変を有する患者において癌を予測及び予防する方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996018648A1 (en) * 1994-12-14 1996-06-20 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Superagonists and antagonists of h il-6, and 3d modelling method for their selection
EP0783893A1 (en) * 1994-10-07 1997-07-16 Chugai Seiyaku Kabushiki Kaisha Rheumatoid arthritis remedy containing il-6 antagonist as active ingredient
WO1998013383A1 (en) * 1996-09-24 1998-04-02 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Adenoviral vectors for mutants of human interleukin 6 (hil-6) with hil-6 antagonist activity, pharmaceutical compositions therewith and their uses
WO1999048523A2 (en) * 1998-03-26 1999-09-30 Glaxo Group Limited Antagonists of the inflammatory mediator oncostatin m (osm)

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5171840A (en) 1988-01-22 1992-12-15 Tadamitsu Kishimoto Receptor protein for human B cell stimulatory factor-2
US6428979B1 (en) 1988-01-22 2002-08-06 Tadamitsu Kishimoto Receptor protein for human B cell stimulatory factor-2
US5670373A (en) * 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
JP2914672B2 (ja) 1989-01-17 1999-07-05 中外製薬株式会社 Ｂｓｆ▲下２▼アンタゴニスト
US5216128A (en) 1989-06-01 1993-06-01 Yeda Research And Development Co., Ltd. IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it
DE122009000023I2 (de) 1989-07-20 2010-12-16 Kishimoto Antikörper gegen menschlichen Interleukin-6-Rezeptor
JP2898064B2 (ja) 1989-08-03 1999-05-31 忠三 岸本 ヒトｇｐ１３０蛋白質
JPH03155795A (ja) 1989-11-13 1991-07-03 Chuzo Kishimoto マウス・インターロイキン―６レセプター蛋白質
JP2898040B2 (ja) 1990-01-26 1999-05-31 忠三 岸本 ｇｐ１３０蛋白質に対する抗体
US5210075A (en) 1990-02-16 1993-05-11 Tanabe Seiyaku Co., Ltd. Interleukin 6 antagonist peptides
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
KR100249937B1 (ko) 1991-04-25 2000-04-01 나가야마 오사무 인간 인터루킨-6 수용체에 대한 재구성 인간 항체
CA2119930C (en) 1991-09-23 2002-10-01 Hendricus R. J. M. Hoogenboom Production of chimeric antibodies - a combinatorial approach
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
CA2131151A1 (en) 1992-03-24 1994-09-30 Kevin S. Johnson Methods for producing members of specific binding pairs
AU675661B2 (en) 1992-07-24 1997-02-13 Abgenix, Inc. Generation of xenogeneic antibodies
FR2694767B1 (fr) 1992-08-13 1994-10-21 Innotherapie Lab Sa Anticorps monoclonaux anti-IL6R, et leurs applications.
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
US5888510A (en) * 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
WO1995009873A1 (en) 1993-10-06 1995-04-13 Board Of Regents, The University Of Texas System A monoclonal anti-human il-6 receptor antibody
CA2177367A1 (en) 1993-12-03 1995-06-08 Andrew David Griffiths Recombinant binding proteins and peptides
JPH07324097A (ja) 1994-05-30 1995-12-12 Daicel Chem Ind Ltd インターロイキン６拮抗剤、及びペプチド類または医薬として許容されるその塩類
US8017121B2 (en) 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
JP3630453B2 (ja) 1994-09-30 2005-03-16 中外製薬株式会社 Ｉｌ−６レセプター抗体を有効成分とする未熟型骨髄腫細胞治療剤
EP0791359A4 (en) 1994-10-21 2002-09-11 Chugai Pharmaceutical Co Ltd MEDICINE AGAINST IL-6 PRODUCTION IN DISEASES
IT1274350B (it) 1994-12-06 1997-07-17 Angeletti P Ist Richerche Bio Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130
ES2170815T5 (es) 1994-12-29 2012-11-14 Chugai Seiyaku Kabushiki Kaisha Uso de un anticuerpo PM-1 o de un anticuerpo MH166 para potenciar el efecto antitumoral de cisplatino o carboplatino
JP4540132B2 (ja) 1995-02-13 2010-09-08 中外製薬株式会社 Ｉｌ−６レセプター抗体を含んでなる筋蛋白分解抑制剤
WO1996030394A1 (en) 1995-03-31 1996-10-03 Jakob Bohr Method for protein folding
FR2733250B1 (fr) 1995-04-21 1997-07-04 Diaclone Anticorps monoclonaux anti-gp130, et leurs utilisations
CA2761116A1 (en) 1995-04-27 1996-10-31 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
JPH08311098A (ja) 1995-05-22 1996-11-26 Daicel Chem Ind Ltd 新規ペプチド類およびそれを含有するインターロイキン６拮抗剤
US5571513A (en) 1995-05-31 1996-11-05 The Board Of Regents Of The University Of Oklahoma Anti-gp130 monoclonal antibodies
JP3471195B2 (ja) 1996-06-27 2003-11-25 中外製薬株式会社 ナイトロジェンマスタード系抗癌剤と組合わせて使用するための骨髄腫治療剤
AU736282B2 (en) 1997-03-21 2001-07-26 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell- mediated diseases comprising IL-6 antagonist as an active ingredient
US20020187150A1 (en) 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
DE69937994T2 (de) 1998-03-17 2008-12-24 Chugai Seiyaku K.K. Prophylaktische oder therapeutische mittel gegen entzündliche erkrankungen des verdauungstraktes enthaltend antagonistische il-6 rezeptor antikörper
US6537782B1 (en) 1998-06-01 2003-03-25 Chugai Seiyaku Kabushiki Kaisha Media for culturing animal cells and process for producing protein by using the same
US6406909B1 (en) 1998-07-10 2002-06-18 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
EP1108435B1 (en) 1998-08-24 2007-01-03 Chugai Seiyaku Kabushiki Kaisha Preventives or remedies for pancreatitis containing anti-il-6 receptor antibodies as the active ingredient
JP4812228B2 (ja) 2000-08-10 2011-11-09 中外製薬株式会社 抗体含有溶液の凝集物生成または白濁抑制方法
US8632778B2 (en) 2000-08-11 2014-01-21 Chugai Seiyaku Kabushiki Kaisha Stabilized anti-interleukin-6 antibody-containing preparations
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
CA2423227C (en) 2000-10-12 2011-11-29 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US7320792B2 (en) 2000-10-25 2008-01-22 Chugai Seiyaku Kabushiki Kaisha Preventives or remedies for psoriasis containing as the active ingredient IL-6 antagonist
AU2000279624A1 (en) 2000-10-27 2002-05-15 Chugai Seiyaku Kabushiki Kaisha Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient
JP4889187B2 (ja) 2000-10-27 2012-03-07 中外製薬株式会社 Ｉｌ−６アンタゴニストを有効成分として含有する血中ｍｍｐ−３濃度低下剤
US7332289B2 (en) 2001-03-09 2008-02-19 Chugai Seiyaku Kabushiki Kaisha Method of purifying protein
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
PL213311B1 (pl) 2002-02-14 2013-02-28 Chugai Pharmaceutical Co Ltd Preparat roztworu zawierajacego przeciwcialo
MXPA04009243A (es) 2002-04-12 2005-06-08 Pfizer Uso de ligandos para el receptor ep4 en el tratamiento de enfermedades vinculadas a il-6.
JP3822137B2 (ja) 2002-05-20 2006-09-13 中外製薬株式会社 動物細胞培養用培地の添加剤およびそれを用いたタンパク質の製造方法
CN100522989C (zh) 2002-09-11 2009-08-05 中外制药株式会社 纯化蛋白质的方法
DE10255508A1 (de) 2002-11-27 2004-06-17 Forschungszentrum Jülich GmbH Verfahren zur Kultivierung von Zellen zur Produktion von Substanzen
WO2004073741A1 (ja) 2003-02-24 2004-09-02 Chugai Seiyaku Kabushiki Kaisha インターロイキン－６アンタゴニストを含有する脊髄損傷治療剤
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
ES2609010T3 (es) 2003-04-04 2017-04-18 Genentech, Inc. Formulaciones de anticuerpos y de proteínas a concentración elevada
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
JP4651541B2 (ja) 2003-10-17 2011-03-16 中外製薬株式会社 中皮腫治療剤
US8617550B2 (en) 2003-12-19 2013-12-31 Chugai Seiyaku Kabushiki Kaisha Treatment of vasculitis with IL-6 antagonist
AR048210A1 (es) 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
AR048335A1 (es) 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
EP3269738A1 (en) 2004-03-24 2018-01-17 Chugai Seiyaku Kabushiki Kaisha Subtypes of humanized antibody against interleukin-6 receptor
DK1835022T3 (en) 2005-01-05 2015-02-23 Chugai Pharmaceutical Co Ltd CELL CULTIVATION PROCEDURE AND UTILIZATION OF THIS
EP1941907B1 (en) 2005-10-14 2016-03-23 Fukuoka University Inhibitor of transplanted islet dysfunction in islet transplantation
EP1941908B1 (en) 2005-10-21 2015-08-19 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for heart disease
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
TW200803894A (en) 2005-11-25 2008-01-16 Univ Keio Prostate cancer therapeutic agents
WO2007074880A1 (ja) 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
WO2007086490A1 (ja) 2006-01-27 2007-08-02 Keio University 脈絡膜血管新生を伴う疾患の治療剤
CN101371140B (zh) 2006-03-09 2013-11-13 弗·哈夫曼-拉罗切有限公司 抗药物抗体的测定
EP2025346B1 (en) 2006-04-07 2016-08-10 Osaka University Muscle regeneration promoter
JP5330829B2 (ja) 2006-08-04 2013-10-30 憲弘 西本 関節リウマチ患者の治療予後予測方法
JP2010095445A (ja) 2006-12-27 2010-04-30 Tokyo Medical & Dental Univ Ｉｌ−６アンタゴニストを有効成分とする炎症性筋疾患治療剤
CN101646459B (zh) 2007-01-23 2014-02-12 国立大学法人信州大学 慢性排斥反应抑制剂
WO2009014263A1 (ja) 2007-07-26 2009-01-29 Osaka University インターロイキン６受容体阻害剤を有効成分とする眼炎症疾患治療剤
US20110245473A1 (en) 2007-09-26 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Anti-IL-6 Receptor Antibody
MX2010003139A (es) 2007-10-02 2010-04-07 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para la enfermedad de injerto contra hospedero que comprenden un inhibidor del receptor de interleucina 6 como ingrediente activo.
JP2009092508A (ja) 2007-10-09 2009-04-30 Norihiro Nishimoto リウマチ治療剤の効果の予測方法
CN101896820A (zh) 2007-12-15 2010-11-24 霍夫曼-拉罗奇有限公司 区分测定
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
WO2009148148A1 (ja) 2008-06-05 2009-12-10 国立がんセンター総長が代表する日本国 神経浸潤抑制剤
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US20120183539A1 (en) 2009-07-31 2012-07-19 Shin Maeda Cancer Metastasis Inhibitor
BR112012009828B8 (pt) 2009-10-26 2022-10-25 Hoffmann La Roche Método para a produção de uma imunoglobulina glicosilada e seu uso
WO2011128096A1 (en) 2010-04-16 2011-10-20 Roche Diagnostics Gmbh Polymorphism markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
JP5904552B2 (ja) 2010-05-28 2016-04-13 国立研究開発法人国立がん研究センター 膵癌治療剤
JP6051049B2 (ja) 2010-05-28 2016-12-21 中外製薬株式会社 抗腫瘍ｔ細胞応答増強剤
WO2011154139A2 (en) 2010-06-07 2011-12-15 Roche Diagnostics Gmbh Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
CA2817216A1 (en) 2010-11-08 2012-05-18 F. Hoffmann-La Roche Ag Subcutaneously administered anti-il-6 receptor antibody
BR112014004828B8 (pt) 2011-09-01 2022-03-29 Chugai Pharmaceutical Co Ltd Métodos para preparação de composições compreendendo anticorpos ou proteínas concentradas por ultrafiltração

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0783893A1 (en) * 1994-10-07 1997-07-16 Chugai Seiyaku Kabushiki Kaisha Rheumatoid arthritis remedy containing il-6 antagonist as active ingredient
WO1996018648A1 (en) * 1994-12-14 1996-06-20 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Superagonists and antagonists of h il-6, and 3d modelling method for their selection
WO1998013383A1 (en) * 1996-09-24 1998-04-02 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Adenoviral vectors for mutants of human interleukin 6 (hil-6) with hil-6 antagonist activity, pharmaceutical compositions therewith and their uses
WO1999048523A2 (en) * 1998-03-26 1999-09-30 Glaxo Group Limited Antagonists of the inflammatory mediator oncostatin m (osm)

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DANIEL WENDLING ET AL.: "Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody", THE JOURNAL OF RHEUMATOLOGY, vol. 20, 1993, pages 259 - 262, XP002917899 *
G. CARROLL ET AL.: "Antagonism of the IL-6 cytokine subfamily- a potential strategy for more effective therapy in rheumatoid arthritis", INFLAMM. RES., vol. 47, 1998, pages 1 - 7, XP002115636 *
LEPORE L. ET AL.: "Study of IL-2, IL-6, TNF alpha, IFN gamma and beta in the serum and synovial fluis of patients with juvenile chronic arthritis", CLIN. EXP. THEUMATOL., vol. 12, no. 5, 1994, pages 561 - 565, XP002953582 *
M.J. ELLIOTT ET AL.: "Suppression of fever and the acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factor-alpha (cA2)", BRITISH JOURNAL OF RHEUMATOLOGY, vol. 36, 1997, pages 589 - 593, XP002953580 *
OEN K. ET AL.: "Interleukin 6 and autoantibodies in juvenile rheumatoid arthritis", J. RHEUMATOL., vol. 20, no. 11, 1993, pages 1949 - 1956, XP002953581 *
ROONEY M. ET AL.: "Inflammatory cytokine responses in juvenile chronic arthritis", BR. J. RHEUMATO., vol. 34, no. 5, 1995, pages 454 - 460, XP002953583 *
See also references of EP1374900A4 *
TAKE H. ET AL.: "Successful treatment with aurranofin in a patient with elderly-onset Still's disease", J. MED., vol. 25, no. 6, 1994, pages 393 - 397, XP002953584 *

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3167901A1 (en) 2003-04-28 2017-05-17 Chugai Seiyaku Kabushiki Kaisha Methods for treating interleukin-6 related diseases
EP3903819A1 (en) 2003-04-28 2021-11-03 Chugai Seiyaku Kabushiki Kaisha Methods for treating interleukin-6 related diseases
EP4098279A1 (en) 2003-04-28 2022-12-07 Chugai Seiyaku Kabushiki Kaisha Methods for treating interleukin-6 related diseases
EP2368577A2 (en) 2003-04-28 2011-09-28 Chugai Seiyaku Kabushiki Kaisha Methods for treating interleukin-6 related diseases
JP2012162552A (ja) * 2004-02-26 2012-08-30 Baylor Research Inst 関節炎の全身処置のための組成物および方法
JP2007525524A (ja) * 2004-02-26 2007-09-06 ベイラー・リサーチ・インスチチユート 関節炎の全身処置のための組成物および方法
US8945558B2 (en) 2005-10-21 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Methods for treating myocardial infarction comprising administering an IL-6 inhibitor
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US9260516B2 (en) 2006-04-07 2016-02-16 Osaka University Method for promoting muscle regeneration by administering an antibody to the IL-6 receptor
US7919095B2 (en) 2006-08-03 2011-04-05 Vaccinex, Inc. Anti-IL-6 monoclonal antibodies
WO2008078715A1 (ja) * 2006-12-27 2008-07-03 Chugai Seiyaku Kabushiki Kaisha Ｉｌ－６アンタゴニストを有効成分とする炎症性筋疾患治療剤
US9725514B2 (en) 2007-01-23 2017-08-08 Shinshu University Chronic rejection inhibitor
US11332533B2 (en) 2007-09-26 2022-05-17 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
US11248053B2 (en) 2007-09-26 2022-02-15 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US11359194B2 (en) 2008-04-11 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
US11371039B2 (en) 2008-04-11 2022-06-28 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US10717781B2 (en) 2008-06-05 2020-07-21 National Cancer Center Neuroinvasion inhibitor
US10662245B2 (en) 2008-09-26 2020-05-26 Chugai Seiyaku Kabushiki Kaisha Methods of reducing IL-6 activity for disease treatment
EP4115906A1 (en) 2010-05-28 2023-01-11 Chugai Seiyaku Kabushiki Kaisha Antitumor t cell response enhancer
WO2011149051A1 (ja) 2010-05-28 2011-12-01 中外製薬株式会社 抗腫瘍t細胞応答増強剤
WO2011149046A1 (ja) 2010-05-28 2011-12-01 独立行政法人国立がん研究センター 膵癌治療剤
US9539322B2 (en) 2010-05-28 2017-01-10 National University Corporation Hokkaido University Method of enhancing an antitumor T cell response by administering an anti-IL-6 receptor antibody
US11285208B2 (en) 2010-05-28 2022-03-29 National Cancer Center Therapeutic agents for pancreatic cancer
US11891434B2 (en) 2010-11-30 2024-02-06 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
WO2013176471A1 (ko) 2012-05-21 2013-11-28 한국생명공학연구원 곰보배추의 추출물 또는 이의 분획물을 유효성분으로 포함하는, stat3 매개 질환의 예방 또는 치료용 약학적 조성물
US10782290B2 (en) 2013-06-11 2020-09-22 National Center Of Neurology And Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
CN103739669A (zh) * 2013-12-31 2014-04-23 罗瑞雪 一种抑制白介素-6多肽及其应用
CN103739669B (zh) * 2013-12-31 2015-08-26 浙江元太生物科技有限公司 一种抑制白介素-6多肽及其应用
US10774148B2 (en) 2015-02-27 2020-09-15 Chugai Seiyaku Kabushiki Kaisha Composition for treating IL-6-related diseases
US10697883B2 (en) 2015-05-19 2020-06-30 National Center Of Neurology And Psychiatry Method for determining application of therapy to multiple sclerosis (MS) patient
US11174317B2 (en) 2015-06-04 2021-11-16 National Center Of Neurology And Psychiatry Therapeutic agent for mental illness comprising IL-6 inhibitor as active ingredient
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion

Also Published As

Publication number Publication date
EP1374900A1 (en) 2004-01-02
US20110206664A1 (en) 2011-08-25
HUP0303952A2 (hu) 2004-03-01
JP2009073857A (ja) 2009-04-09
HUP0303952A3 (en) 2012-09-28
AU2002243032B2 (en) 2008-01-31
MXPA03008955A (es) 2004-02-18
JPWO2002080969A1 (ja) 2004-07-29
CA2443294A1 (en) 2002-10-17
US20160194401A1 (en) 2016-07-07
EP2298812A2 (en) 2011-03-23
JP3702274B2 (ja) 2005-10-05
NO20034388L (no) 2003-10-21
CN1499983A (zh) 2004-05-26
CA2443294C (en) 2013-09-24
RU2361613C2 (ru) 2009-07-20
IL158079A0 (en) 2004-03-28
RU2008102979A (ru) 2009-08-10
NO20034388D0 (no) 2003-10-01
KR100842133B1 (ko) 2008-06-27
JP5591279B2 (ja) 2014-09-17
UA80091C2 (en) 2007-08-27
KR20080027401A (ko) 2008-03-26
US20040115197A1 (en) 2004-06-17
IL158079A (en) 2012-01-31
JP2012140464A (ja) 2012-07-26
US7955598B2 (en) 2011-06-07
PL365339A1 (en) 2004-12-27
RU2541165C2 (ru) 2015-02-10
IL187604A (en) 2011-12-29
JP3702289B2 (ja) 2005-10-05
IL187604A0 (en) 2009-02-11
US9255145B2 (en) 2016-02-09
HU230197B1 (hu) 2015-10-28
BR0208636A (pt) 2004-03-09
EP1374900A4 (en) 2004-07-21
CN100562339C (zh) 2009-11-25
KR100842132B1 (ko) 2008-06-27
EP2298812A3 (en) 2011-07-13
US20070148169A1 (en) 2007-06-28
RU2003132066A (ru) 2005-04-10
US20180222988A1 (en) 2018-08-09
KR20030087655A (ko) 2003-11-14
EP1972638A1 (en) 2008-09-24
EP3640261A1 (en) 2020-04-22
JP2005139205A (ja) 2005-06-02
PL216534B1 (pl) 2014-04-30
NZ528479A (en) 2005-08-26
JP2005206604A (ja) 2005-08-04
HK1062408A1 (en) 2004-11-05

Similar Documents

Publication Publication Date Title
WO2002080969A1 (fr) Remedes pour des maladies liees a l'arthrite chronique du nourrisson
AU2000279625A1 (en) Blood mmp-3 level-lowering agent containing il-6 antgonist as the active ingredient
AU1095202A (en) Preventives or remedies for psoriasis containing as the active ingredient il-6 antagonist
AU2002210952A1 (en) Preventives or remedies for psoriasis containing as the active ingredient IL-6 antagonist
CA2458067A1 (en) Use of flibanserin in the treatment of sexual disorders
HUP0101694A3 (en) Preventives or remedies for inflammatory intestinal diseases containing as the active ingredient il-6 antagonists
PT1441705E (pt) Sistemas terapêuticos sólidos, estabilizados, de libertação rápida e/ou modificada para a administração oral de princípios ativos, excipientes ou produtos alimentares líquidos
EP1425277B8 (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain
MXPA03006775A (es) Formulacion farmaceutica.
WO2005045689A8 (en) Methods and systems for network coordination
AU6420798A (en) A preventive or therapeutic agent for sensitized T cell- mediated diseases comprising IL-6 antagonist as an active ingredient
WO2003037860A3 (en) Purine analogs having hsp90-inhibiting activity
AU2002318759A1 (en) Remedies for diseases with bone mass loss having EP4 agonists as the active ingredient
MXPA03007641A (es) Formulacion farmaceutica.
HUP0400155A3 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
ZA200402729B (en) Pharmaceutical formulation comprising (R) -bicalutamide.
AU2002315848A1 (en) Remedies for eosinophilic diseases
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration
AU2001258442A1 (en) Drug delivery device, especially for the delivery of levonorgestrel
EP1361866A4 (en) EMULSIONS AS SOLID DOSAGE FORMS FOR ORAL ADMINISTRATION
GB0128071D0 (en) Medicament
Torabi The woman from the perspective of Revelation
AU2002324469A1 (en) Substituted-heteroaryl-7-aza(2.2.1)bicycloheptanes for the treatment of disease
WO2002083110A3 (en) Animal model for evaluating analgesics
AU2002338027A1 (en) Remedies for diseases caused by beta-amyloids containing 2-100beta inhibitor as the active ingredient

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002579008

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002243032

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 158079

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 528479

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1020037012661

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 10473165

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 028077849

Country of ref document: CN

REEP Request for entry into the european phase

Ref document number: 2002708772

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/008955

Country of ref document: MX

Ref document number: 2002708772

Country of ref document: EP

Ref document number: 2443294

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2002708772

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 528479

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 528479

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 187604

Country of ref document: IL